

Special Issue

Psychological Aspects of COVID-19 Vaccine Uptake: Principles and Empirical Strategies

Message from the Guest Editors

As you are all well aware, developing a vaccine for COVID-19 is our best hope for successfully confronting the current global epidemic. However, coming up with an effective vaccine (or several of them) is not enough: People need to actually take the vaccine. To achieve a more extensive understanding of recent scientific knowledge as it applies to possible COVID-19-related vaccines, this Special Issue will focus on the critical issues, challenges, successes, and new ways of thinking about uptake of a COVID-19 vaccine. We invite you to contribute with an original report, observation or review, highlighting (i) prevalence of acceptance, hesitancy or refusal to accept a COVID-19 vaccine; (ii) associated attributes or factors driving hesitancy/refusal ranging from the personal and relational to the community and cultural; (iii) experimental work testing intention/behavior change in relation to the uptake vaccination; and (iv) the influence of media on the decision-making process— from literacy to social media.

Guest Editors

Prof. Dr. Efrat Neter

Department of Behavioral Sciences, Ruppin Academic Center, Emeq Hefer 4025000, Israel

Prof. Dr. Karen Morgan

1. Perdana University-Royal College of Surgeons in Ireland School of Medicine, Perdana University, Kuala Lumpur 50490, Malaysia
2. Department of Health Psychology, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland

Deadline for manuscript submissions

closed (31 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/62634

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).